IN2015DN02699A - - Google Patents
Info
- Publication number
- IN2015DN02699A IN2015DN02699A IN2699DEN2015A IN2015DN02699A IN 2015DN02699 A IN2015DN02699 A IN 2015DN02699A IN 2699DEN2015 A IN2699DEN2015 A IN 2699DEN2015A IN 2015DN02699 A IN2015DN02699 A IN 2015DN02699A
- Authority
- IN
- India
- Prior art keywords
- dosages
- eye
- compositions
- methods
- relates
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2012/052177 WO2014037686A1 (en) | 2012-09-05 | 2012-09-05 | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN02699A true IN2015DN02699A (de) | 2015-09-04 |
Family
ID=46889366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2699DEN2015 IN2015DN02699A (de) | 2012-09-05 | 2012-09-05 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10011832B2 (de) |
| EP (1) | EP2893018B1 (de) |
| JP (1) | JP2015533792A (de) |
| KR (1) | KR102120060B1 (de) |
| CN (1) | CN104781402A (de) |
| AU (1) | AU2012389270B2 (de) |
| BR (1) | BR112015004452A2 (de) |
| CA (1) | CA2883007A1 (de) |
| CL (1) | CL2015000538A1 (de) |
| EC (1) | ECSP15011105A (de) |
| ES (1) | ES2750125T3 (de) |
| HK (1) | HK1211983A1 (de) |
| IL (1) | IL237403B (de) |
| IN (1) | IN2015DN02699A (de) |
| MX (1) | MX368084B (de) |
| RU (1) | RU2653766C2 (de) |
| SG (1) | SG11201501385UA (de) |
| WO (1) | WO2014037686A1 (de) |
| ZA (1) | ZA201502181B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015004452A2 (pt) | 2012-09-05 | 2017-08-08 | Sylentis Sau | sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares |
| US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| WO2024230837A1 (zh) * | 2023-05-11 | 2024-11-14 | 广州瑞风生物科技有限公司 | 指导rna、基因编辑系统及其应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343794A (en) | 1980-05-06 | 1982-08-10 | Mt. Sinai | Method of reducing intraocular pressure with salts of vanadic acid |
| US4652586A (en) | 1980-11-07 | 1987-03-24 | The General Hospital Corporation | Selective beta-2 adrenergic antagonists for the treatment of glaucoma |
| SU986484A1 (ru) * | 1981-07-20 | 1983-01-07 | Каунасский Политехнический Институт Им.Антанаса Снечкуса | Дозатор жидкости |
| US4617299A (en) | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US5242943A (en) | 1984-03-28 | 1993-09-07 | William J. Louis | 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them |
| US4812448A (en) | 1984-10-22 | 1989-03-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US4757089A (en) | 1985-06-14 | 1988-07-12 | Massachusetts Eye And Ear Infirmary | Increasing aqueous humor outflow |
| US5075323A (en) | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
| US5260059A (en) | 1989-04-14 | 1993-11-09 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor |
| RU2039539C1 (ru) * | 1990-09-27 | 1995-07-20 | Менчел Йехошуа | Насадка для установки на флаконе с лекарственной жидкостью и устройство для распределения глазной жидкости |
| US6372249B1 (en) | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
| US5464866A (en) | 1992-08-17 | 1995-11-07 | Alcon Laboratories, Inc. | Substituted hydrindanes for the treatment of angiogenesis-dependent diseases |
| US5545626A (en) | 1994-01-19 | 1996-08-13 | The Trustees Of Columbia University In The City Of New York | Method of treating glaucoma with oligonucleotides |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| US20020055536A1 (en) | 1996-09-26 | 2002-05-09 | Dewitte Robert S. | System and method for structure-based drug design that includes accurate prediction of binding free energy |
| US6489307B1 (en) | 1998-09-14 | 2002-12-03 | University Of Florida | Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use |
| AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| US6365576B1 (en) | 1999-06-24 | 2002-04-02 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for inhibiting herpes infection |
| PT1407044E (pt) | 2000-12-01 | 2008-01-02 | Max Planck Ges Zur Forderung W | Moléculas curtas de arn que medeiam a interferência de arn |
| US20020165158A1 (en) | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20070049543A1 (en) | 2001-05-18 | 2007-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA |
| US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| AU2002361861A1 (en) | 2001-12-21 | 2003-07-30 | Rhode Island Hospital | SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF |
| US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| GB2406568B (en) | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003222820A1 (en) | 2002-04-18 | 2003-10-27 | Acuity Pharmaceuticals, Inc. | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| WO2003092584A2 (en) | 2002-04-30 | 2003-11-13 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| US20040115641A1 (en) | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of ROCK 1 expression |
| DE20209155U1 (de) | 2002-06-13 | 2003-10-23 | Dr. Eugen Beck GmbH & Co., 59302 Oelde | Brille, insbesondere fassungslose Bohr-Brille |
| AU2003256381A1 (en) * | 2002-07-03 | 2004-01-23 | Pericor Science, Inc | Compositions of hyaluronic acid and methods of use |
| CA2493564A1 (en) | 2002-07-24 | 2004-01-29 | Immusol, Inc. | Novel sirna libraries and their production and use |
| EP1554386A2 (de) | 2002-07-24 | 2005-07-20 | Immusol Incorporated | Ein-promotor-system zur herstellung von sirna-expressionskassetten und -expressionsbibliotheken unter verwendung eines polymerase-primer-haarnadellinkers |
| PT1527176E (pt) | 2002-08-05 | 2007-04-30 | Atugen Ag | Novas formas de muléculas de arn de interferência |
| US20040029275A1 (en) | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| ATE513843T1 (de) | 2002-09-25 | 2011-07-15 | Univ Massachusetts | Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna |
| AU2003291678B2 (en) | 2002-11-01 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
| DE10322662A1 (de) | 2002-11-06 | 2004-10-07 | Grünenthal GmbH | Wirksame und stabile DNA-Enzyme |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| WO2004045543A2 (en) | 2002-11-14 | 2004-06-03 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
| US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| GB0307206D0 (en) | 2003-03-28 | 2003-04-30 | Axordia Ltd | Hyperproliferation |
| US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
| WO2004099372A2 (en) | 2003-05-01 | 2004-11-18 | University Of Florida | Anti-scarring ribozymes and methods |
| US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
| EP1636342A4 (de) | 2003-06-20 | 2008-10-08 | Isis Pharmaceuticals Inc | Oligomere verbindungen zur verwendung bei der modulation von genen |
| US7338950B2 (en) | 2003-10-07 | 2008-03-04 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050208658A1 (en) | 2003-11-21 | 2005-09-22 | The University Of Maryland | RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression |
| EP1711510A4 (de) | 2004-02-05 | 2008-11-26 | Intradigm Corp | Rnai-therapeutika zur behandlung von augenkrankheiten mit gefässneubildung |
| GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| EP1735009A4 (de) | 2004-03-12 | 2011-03-30 | Alnylam Pharmaceuticals Inc | Irna mittel targeting vegf |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| WO2005117938A2 (en) | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
| IL179285A (en) | 2004-05-14 | 2011-04-28 | Rosetta Genomics Ltd | Micrornas and uses thereof |
| US7687665B2 (en) | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
| AU2005272816B2 (en) | 2004-08-10 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| PL1781787T3 (pl) | 2004-08-23 | 2018-01-31 | Sylentis Sau | Leczenie zaburzeń oka charakteryzowanych przez podwyższone ciśnienie wewnątrzgałkowe przy użyciu siRNA |
| TW200639252A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
| EP1856259A1 (de) | 2005-03-11 | 2007-11-21 | Alcon Inc. | Rnai-vermittelte hemmung von frizzled-verwandtem protein-1 zur behandlung von glaukomen |
| CN101517081A (zh) | 2006-08-24 | 2009-08-26 | 爱尔康研究有限公司 | RNAi介导的Gremlin抑制用于治疗眼内压相关的状况 |
| WO2008104978A2 (en) | 2007-02-28 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| BR112015004452A2 (pt) | 2012-09-05 | 2017-08-08 | Sylentis Sau | sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares |
-
2012
- 2012-09-05 BR BR112015004452A patent/BR112015004452A2/pt not_active Application Discontinuation
- 2012-09-05 SG SG11201501385UA patent/SG11201501385UA/en unknown
- 2012-09-05 CA CA2883007A patent/CA2883007A1/en not_active Abandoned
- 2012-09-05 ES ES12762372T patent/ES2750125T3/es active Active
- 2012-09-05 IN IN2699DEN2015 patent/IN2015DN02699A/en unknown
- 2012-09-05 CN CN201280076706.5A patent/CN104781402A/zh active Pending
- 2012-09-05 RU RU2015112131A patent/RU2653766C2/ru active
- 2012-09-05 KR KR1020157008532A patent/KR102120060B1/ko active Active
- 2012-09-05 EP EP12762372.6A patent/EP2893018B1/de active Active
- 2012-09-05 JP JP2015530486A patent/JP2015533792A/ja active Pending
- 2012-09-05 MX MX2015002800A patent/MX368084B/es active IP Right Grant
- 2012-09-05 AU AU2012389270A patent/AU2012389270B2/en active Active
- 2012-09-05 WO PCT/GB2012/052177 patent/WO2014037686A1/en active Application Filing
- 2012-09-05 US US14/425,466 patent/US10011832B2/en active Active
-
2015
- 2015-02-25 IL IL23740315A patent/IL237403B/en active IP Right Grant
- 2015-03-04 CL CL2015000538A patent/CL2015000538A1/es unknown
- 2015-03-23 EC ECIEPI201511105A patent/ECSP15011105A/es unknown
- 2015-03-30 ZA ZA2015/02181A patent/ZA201502181B/en unknown
-
2016
- 2016-01-05 HK HK16100040.2A patent/HK1211983A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015004452A2 (pt) | 2017-08-08 |
| KR102120060B1 (ko) | 2020-06-09 |
| HK1211983A1 (en) | 2016-06-03 |
| WO2014037686A1 (en) | 2014-03-13 |
| AU2012389270B2 (en) | 2018-11-08 |
| CA2883007A1 (en) | 2014-03-13 |
| KR20150048880A (ko) | 2015-05-07 |
| JP2015533792A (ja) | 2015-11-26 |
| ES2750125T3 (es) | 2020-03-25 |
| ZA201502181B (en) | 2016-01-27 |
| EP2893018B1 (de) | 2019-07-24 |
| RU2653766C2 (ru) | 2018-05-14 |
| AU2012389270A1 (en) | 2015-02-26 |
| IL237403A0 (en) | 2015-04-30 |
| US10011832B2 (en) | 2018-07-03 |
| SG11201501385UA (en) | 2015-03-30 |
| EP2893018A1 (de) | 2015-07-15 |
| IL237403B (en) | 2019-11-28 |
| RU2015112131A (ru) | 2016-10-27 |
| CL2015000538A1 (es) | 2015-07-31 |
| MX2015002800A (es) | 2015-07-17 |
| US20150259677A1 (en) | 2015-09-17 |
| ECSP15011105A (es) | 2015-12-31 |
| CN104781402A (zh) | 2015-07-15 |
| MX368084B (es) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202110854B (en) | Tmprss6 irna compositions and methods of use thereof | |
| WO2013155204A3 (en) | Compositions and methods for inhibiting expression of the alas1 gene | |
| MX2019006413A (es) | Composiciones de arni de serpinc1 y metodos de uso de las mismas. | |
| MX2019009283A (es) | Composiciones de arni de proteina convertasa subtilisina kexina 9 (pcsk9) y metodos de uso de las mismas. | |
| NZ712336A (en) | Complement component c5 irna compositions and methods of use thereof | |
| MX2018013216A (es) | Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6). | |
| SG10201804472YA (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
| WO2014028429A3 (en) | Enzymes and polymerases for the synthesis of rna | |
| SG10201804960RA (en) | Complement component irna compositions and methods of use thereof | |
| MX384253B (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica | |
| MX361862B (es) | Composiciones y métodos que comprenden variante de enzima lipolítica. | |
| WO2015085318A3 (en) | Targeted adaptive vaccines | |
| MX344972B (es) | Oligonucleotidos inmunoestimulantes. | |
| PH12013501654A1 (en) | Pesticidal compositions and processes related thereto | |
| MX2015011779A (es) | Nucleosidos biciclicos unidos en puente. | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| MX2022001017A (es) | Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1). | |
| WO2013053857A3 (en) | Gene cluster for biosynthesis of griselimycin and methylgriselimycin | |
| IN2015DN02699A (de) | ||
| MY185464A (en) | Complement component c5 irna compositions and methods of use thereof | |
| EA037110B9 (ru) | КОМПОЗИЦИИ С иРНК К PCSK9 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| UA105703C2 (uk) | 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти |